BI 695501 autoinjector

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Arthritis, RheumatoidHealthy

Phase 1

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

CompletedNCT02606903

Boehringer IngelheimHealthy

Start: 2015-10-28End: 2016-10-04Updated: 2018-12-27

Phase 2

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

CompletedNCT02636907

Boehringer IngelheimArthritis, Rheumatoid

Start: 2016-01-06End: 2017-06-29Updated: 2018-07-10

Related Papers

Similar Pharmacokinetics of the Adalimumab (Humira<sup>®</sup>) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE<sup>®</sup>-AI and VOLTAIRE<sup>®</sup>-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials.

2018-06-2912 citations

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE<sup>®</sup>-RL)

Expert Opinion on Drug Delivery2018-05-1510 citations